Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Pfizer Inc. (PFE) - $25 value - yours FREE >>
Merck KGaA (MKGAF) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Inc. (PFE) - $25 value - yours FREE >>
Merck KGaA (MKGAF) - $25 value - yours FREE >>
Image: Bigstock
Merck KGaA Offers Portfolio Updates at Market Day Event
Germany-based Merck KGaA (MKGAF - Free Report) provided an update on its objectives up to 2018 at the company’s 2016 Capital Market Day.
At the Healthcare business, the company aims to obtain approval of one medicine or indication every year starting 2017. Through 2022, Merck expects to generate sales of €2 billion from the products in its pipeline.
Moreover, the company anticipates filling for avelumab for the treatment of metastatic Merkel cell carcinoma this year. Note that avelumab is being developed in collaboration with Pfizer Inc. (PFE - Free Report) .
The Life Science business segment is benefitting from strong demand in the biopharmaceutical space and efficient integration of the Sigma-Aldrich acquisition. The company has realized substantial synergies from this buyout much earlier than planned. By 2016 end, it now expects to leverage €105 million in comparison to the originally planned annually recurring cost synergies of €90 million.
MERCK KGAA Price
MERCK KGAA Price | MERCK KGAA Quote
The company has also announced its plans for growth beyond 2018. It expects to generate sales of €4 billion from new products by 2022.
Stocks to Consider
A couple of favorably placed stocks in the health care sector are Incyte Corporation (INCY - Free Report) and Geron Corporation (GERN - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte’s earnings estimates for 2016 and 2017 were up a respective 29.4% and 9.8% over the last 60 days. The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335.16%.
Geron has delivered a positive earnings surprise in each of four trailing quarters, bringing the average beat to 20.78%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>